Haleon is trading at £317.70, down 15.05%, after cutting its 2026 organic revenue growth guidance.
- Guidance is now around 2.5%, down from 3%–5%, after third-quarter organic growth of 2.6% fell short of expectations.
- Weak cough, cold and flu demand, particularly in North America, and a China regulatory setback weighed on performance.
- Reuters reported a 15% share fall on October 29 following the outlook cut and sales miss.